Monitor the Cantor conference for any clinical or regulatory updates on urcosimod's Phase 3 trial plans. The FDA Type D meeting validation is a positive regulatory signal, but no new data was released. The next catalyst to watch is the initiation of the Phase 3 trial.
Price Chart
Executive Summary
OKYO Pharma filed a 6-K announcing participation at the Cantor Global Healthcare Conference (Sept 9-11, 2026) with a fireside chat and one-on-one meetings. The press release references recent positive FDA Type D meeting feedback validating the regulatory path for urcosimod and a strengthened cash position per its annual report. This is a routine investor relations event with no new material financial or clinical data.
Key Facts
- OKYO Pharma will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026 at 8:35 AM ET.
- The company references recent positive FDA Type D meeting feedback validating the regulatory and clinical path forward for urcosimod.
- The company plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
- The press release mentions the filing of its Annual Report reflecting a strengthened cash position.
Financial Impact
No new financial data or material financial impact disclosed in this filing.
Risk Factors
- No new material information; stock may trade on conference sentiment rather than fundamentals.
- Clinical-stage biotech risk: Phase 3 trial outcomes are binary and uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-041686 |
| Exhibit: ex99-1.htm | 0001493152-26-041686 |
| Document: 0001493152-26-041686-index-headers.html | 0001493152-26-041686 |
| Document: 0001493152-26-041686-index.html | 0001493152-26-041686 |
| Document: 0001493152-26-041686.txt | 0001493152-26-041686 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.51 (+3.42%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.51 (+3.42%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.51 (+11.02%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.51 (−1.31%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.51 (−3.83%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.51 (−7.93%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.51 (−7.93%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.51 (+2.02%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.51 (+2.02%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.51 (+2.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers